Pharmala Biotech Holdings Inc. MDMA
CNSX
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 2.44% | 56.63% | 15.73% | -60.74% | -22.99% |
| Total Depreciation and Amortization | -50.72% | -50.74% | -54.42% | 131.79% | 78.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -75.05% | -- |
| Total Other Non-Cash Items | 29.89% | -69.44% | -43.91% | -121.10% | -48.04% |
| Change in Net Operating Assets | -319.24% | -211.42% | 320.11% | 168.89% | 120.29% |
| Cash from Operations | -22.32% | -3.06% | 52.10% | -7,313.79% | -10.65% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 133.80% | 123.50% | 742.13% | 552.94% | 348.28% |
| Cash from Investing | 133.80% | 123.50% | 742.13% | 546.76% | 348.28% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | -- |
| Cash from Financing | -- | -- | -- | 88.36% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 85.17% | -53.75% | 119.31% | -17.20% | -128.85% |